Flore by Sun Genomics is a technology company.
Flore by Sun Genomics has raised $12.0M across 2 funding rounds.
Flore by Sun Genomics has raised $12.0M in total across 2 funding rounds.
Flore by Sun Genomics is a microbiome health company that develops personalized probiotics and synbiotics based on individual gut microbiome testing. It serves consumers seeking solutions for digestive issues, immunity, fatigue, brain fog, and conditions like autism spectrum disorder (ASD), using at-home stool tests, whole-genome sequencing, and bioinformatics to create custom formulations delivered via monthly subscriptions.[1][2][3][4] The company addresses gut dysbiosis by targeting specific microbial imbalances, with products like custom probiotics, multivitamins (Floré Multi-V), and ASD-focused synbiotics, backed by clinical studies showing improved microbiome diversity and symptom relief.[1][2][4][5]
Growth momentum includes product expansions like the 2023 launch of customizable multivitamins, participation in functional medicine conferences, and ongoing clinical trials, such as a randomized study for neurodiversity applications. Headquartered in San Diego, it has raised funding through incubators and collaborates with academic partners like Arizona State University.[1][2][5]
Floré by Sun Genomics traces its roots to 2014, initially operating as DNA Shirts before rebranding through Sun Genomics, with key sources citing a formal founding around 2016 under Sun Genomics.[1][2][3] Sunny Jain, the founder and former CEO, drove the pivot to microbiome health, leveraging expertise in precision nutrition; current leadership includes CEO Craig Rouskey (MSc) and a team with backgrounds in microbiology, neurobiology, bioinformatics, and immunology.[2][3]
The idea emerged from recognizing gut microbiome's role in overall health, evolving from general genomics to personalized probiotics via patented DNA extraction from stool samples. Early traction came from consumer adoption of at-home testing and custom subscriptions, amplified by clinical collaborations like the 2023 ASU study on ASD, which demonstrated preliminary benefits in gastrointestinal symptoms and neurological support, paving the way for beta-tested formulations.[2][4][5]
Floré rides the personalized medicine and microbiome therapeutics trend, fueled by advances in whole-genome sequencing and AI-driven bioinformatics, amid rising consumer demand for gut-brain axis solutions post-COVID awareness of immunity and mental health links.[2][3][5] Timing is ideal as functional medicine grows—evidenced by their 2023 conference presence and clinical expansions—while market forces like direct-to-consumer testing (competing with Viome) and neurodiversity research create tailwinds.[1][2]
The company influences the ecosystem by partnering with universities (e.g., ASU), labs, and advisors, advancing evidence-based synbiotics and enabling practitioner-led precision nutrition, potentially standardizing custom gut health in wellness and autism care.[3][5]
Next steps include scaling randomized clinical trials to validate ASD and broader applications, expanding product lines like synbiotics and multivitamins, and deepening B2B practitioner integrations.[2][5] Trends in AI-microbiome analytics, regulatory clarity for live biotherapeutics, and holistic health will propel growth, positioning Flore to lead in precision gut solutions amid a $50B+ probiotics market. Its evolution from niche testing to clinically substantiated personalization underscores a transformative role in democratizing microbiome health.
Flore by Sun Genomics has raised $12.0M in total across 2 funding rounds.
Flore by Sun Genomics's investors include Mayfield, Outsized Ventures, SOSV, True Ventures.
Flore by Sun Genomics has raised $12.0M across 2 funding rounds. Most recently, it raised $9.0M Series A in June 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2020 | $9.0M Series A | Mayfield, Outsized Ventures, SOSV, True Ventures | |
| Jan 1, 2019 | $3.0M Seed | Mayfield, Outsized Ventures, SOSV, True Ventures |